Matt Gamber’s Biotech Newsletter
Matt GamberWeekly posts on small and mid-cap biotech stocks. 100% independent and reader supported with no company sponsored content or hedge fund compensation of any kind. See free performance posts for more information. Not financial advice, for research purposes.
| Platform |  | Pricing | Freemium | Publishes | Weekly |
|---|---|---|---|---|---|
| Issues | 90 | Subscribers | Read | mattbiotech.substack.com |
Curious about how many subscribers Matt Gamber’s Biotech Newsletter has or want to find similar newsletters? Reletter has got you covered. We collated all the information we could find from across the web in our database of over three million newsletters.
Check the email archives, get traffic estimates, engagement scores and more to discover the best advertising opportunities.
Our search tool helps you locate relevant newsletters for any topic and compare their stats for better sponsorship decisions.
Latest Issues
Recent posts by this newsletter. Browse the email archive.
Last Boarding On The Tarsus Train
An idea I first wrote about at $42.18 now has the ability to go to $200+ over the long-term if peak sales guidance and loss of exclusivity dates stay in tact.
Zai Lab Is Finally Ready To Blossom
A profitable commercial business in China, a late-stage pipeline with first approval by 2027, and a business model with incredible operating leverage
Anaptysbio, Part 2: Royalty Stream Update And The Celiac Opportunity
The royalty opportunity is already vastly undervalued in my eyes but a disease modifying therapy in Celiac could be a mega-blockbuster drug.
I Can't Believe Esperion Is A Buy
Can a slow-growing drug launch re-accelerate in Year 6? How many eligible patients can't or won't take a statin? Is an oral triple combination the next frontier in cholesterol lowering therapy?
Similar Newsletters
Other publications recommended by the authors of this newsletter.
Authors
The writers behind this newsletter.
Frequently Asked Questions
How can I access the email archive for Matt Gamber’s Biotech Newsletter?
You can find recent issues that have been published by Matt Gamber’s Biotech Newsletter on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does Matt Gamber’s Biotech Newsletter have?
To see how many people subscribe to Matt Gamber’s Biotech Newsletter, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in Matt Gamber’s Biotech Newsletter?
Newsletter advertising can be extremely effective when it's done right. Before you pitch Matt Gamber’s Biotech Newsletter as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like Matt Gamber’s Biotech Newsletter?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Matt Gamber’s Biotech Newsletter using the contact information provided and ask for a copy of their media kit.
How can I find newsletters similar to Matt Gamber’s Biotech Newsletter?
Scroll up to where it says Similar Newsletters to see other publications like Matt Gamber’s Biotech Newsletter. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact Matt Gamber’s Biotech Newsletter?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.